Q1 EPS Estimate for SAB Biotherapeutics Lifted by Analyst

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Equities researchers at HC Wainwright lifted their Q1 2025 earnings per share (EPS) estimates for shares of SAB Biotherapeutics in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst E. White now expects that the company will earn ($1.14) per share for the quarter, up from their prior forecast of ($1.35). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.59) EPS, FY2026 earnings at ($3.59) EPS and FY2027 earnings at ($2.97) EPS.

Separately, Chardan Capital dropped their target price on shares of SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics currently has a consensus rating of “Buy” and a consensus target price of $11.40.

SAB Biotherapeutics Stock Up 1.6 %

NASDAQ SABS opened at $1.25 on Thursday. The stock’s 50 day moving average is $1.89 and its 200 day moving average is $2.81. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. SAB Biotherapeutics has a twelve month low of $1.11 and a twelve month high of $5.01.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Friday, March 28th. The company reported ($1.23) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.07). SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. The company had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.12 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. HB Wealth Management LLC grew its stake in shares of SAB Biotherapeutics by 118.6% in the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after acquiring an additional 128,800 shares during the last quarter. Geode Capital Management LLC raised its position in shares of SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after purchasing an additional 12,692 shares during the last quarter. Diadema Partners LP bought a new position in SAB Biotherapeutics in the 4th quarter worth about $114,000. Kovitz Investment Group Partners LLC purchased a new stake in SAB Biotherapeutics during the 3rd quarter valued at about $52,000. Finally, Northern Trust Corp bought a new stake in SAB Biotherapeutics during the 4th quarter valued at about $43,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.